mk2 Biotechnologies Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 6

Employees

  • Latest Deal Type
  • M&A

mk2 Biotechnologies General Information

Description

Developer of a peptide and protein purification technology designed to revolutionize recombinant production processes. The company's technology facilitates the production of enhanced-purity products, significantly diminishing the purification challenges prevalent in modern chemical and biological synthesis methods to meet specific requirements, enabling the pharmaceuticals, agriculture, and cosmetics industries to efficiently overcome purification and economy-to-scale obstacles encountered in stock breeding.

Contact Information

Website
www.mk2.bio
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Am Klopferspitz 19
  • 82152 Planegg
  • Germany
Primary Industry
Biotechnology
Acquirer
Protevo Bio
Vertical(s)
Corporate Office
  • Am Klopferspitz 19
  • 82152 Planegg
  • Germany

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

mk2 Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 03-Feb-2025 Completed Generating Revenue
8. Early Stage VC 12-Jul-2023 Completed Generating Revenue
7. Accelerator/Incubator 01-Jun-2023 Completed Generating Revenue
6. Accelerator/Incubator 01-Feb-2023 Completed Generating Revenue
5. Accelerator/Incubator 01-Feb-2023 Completed Generating Revenue
4. Seed Round 29-Jul-2021 Completed Generating Revenue
3. Accelerator/Incubator 01-Jan-2021 Completed Generating Revenue
2. Accelerator/Incubator 02-Jun-2020 Completed Generating Revenue
1. Grant 01-Jan-2019 $3.42K Completed Generating Revenue
To view mk2 Biotechnologies’s complete valuation and funding history, request access »

mk2 Biotechnologies Patents

mk2 Biotechnologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025087483-A1 Method of detecting peptides and/or proteins Inactive 24-Oct-2023
JP-2025513487-A Preparation of target peptides and proteins Pending 19-Apr-2022
WO-2023203032-A1 Preparation of target peptides and proteins Inactive 19-Apr-2022 C07K14/79

mk2 Biotechnologies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

mk2 Biotechnologies Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Atlantis Ventures Venture Capital Minority
BioTools Innovator Accelerator/Incubator Minority
EIT Food Accelerator/Incubator Minority
Gateway Ventures Venture Capital Minority
German Accelerator Accelerator/Incubator
You’re viewing 5 of 12 investors. Get the full list »

mk2 Biotechnologies FAQs

  • When was mk2 Biotechnologies founded?

    mk2 Biotechnologies was founded in 2019.

  • Where is mk2 Biotechnologies headquartered?

    mk2 Biotechnologies is headquartered in Planegg, Germany.

  • What is the size of mk2 Biotechnologies?

    mk2 Biotechnologies has 6 total employees.

  • What industry is mk2 Biotechnologies in?

    mk2 Biotechnologies’s primary industry is Biotechnology.

  • Is mk2 Biotechnologies a private or public company?

    mk2 Biotechnologies is a Private company.

  • What is mk2 Biotechnologies’s current revenue?

    The current revenue for mk2 Biotechnologies is .

  • Who are mk2 Biotechnologies’s investors?

    Atlantis Ventures, BioTools Innovator, EIT Food, Gateway Ventures, and German Accelerator are 5 of 12 investors who have invested in mk2 Biotechnologies.

  • When was mk2 Biotechnologies acquired?

    mk2 Biotechnologies was acquired on 03-Feb-2025.

  • Who acquired mk2 Biotechnologies?

    mk2 Biotechnologies was acquired by Protevo Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process